Silexion Therapeutics Ltd.
Silexion Therapeutics Ltd. (SLXNW) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
slxnw · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Silexion Therapeutics Ltd. (SLXNW) measures how much investors pay for each dollar of the company's trailing earnings. SLXNW's current PE ratio of N/A is calculated by dividing its stock price of $0.03 by its TTM earnings per share of -$39.96.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2020 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Silexion Therapeutics Ltd.You SLXNW | $0M | N/A | — | -$39.96 |
 Aclarion, Inc. ACON | $2M | N/A | — | -$13.60 |
 Akari Therapeutics, Plc AKTX | $18M | N/A | — | -$822.15 |
 Dermata Therapeutics, Inc. DRMA | $1M | N/A | — | -$8.16 |
 FOXO Technologies Inc. FOXO | $0M | N/A | — | -$0.05 |
 P3 Health Partners Inc. PIII | $40M | N/A | — | -$45.26 |
 Purple Biotech Ltd. PPBT | $0M | N/A | — | -$10992.95 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-89.60 | — | |
2024-12-31 FY2024 | — | $-26.36 | — | |
2023-12-31 FY2023 | — | $-44.23 | — | |
2022-12-31 FY2022 | — | $-1.92 | — | |
2021-12-31 FY2021 | — | $-0.46 | — | |
2020-12-31 FY2020 | — | $-0.12 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Silexion Therapeutics Ltd. (SLXNW) measures how much investors pay for each dollar of the company's trailing earnings. SLXNW's current PE ratio of N/A is calculated by dividing its stock price of $0.03 by its TTM earnings per share of -$39.96.
Frequently asked questions
SLXNW pe ratio · 6 questionsSLXNW's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.03 and TTM EPS of -$39.96. Data sourced from Financial Modeling Prep via SLXNW's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Silexion Therapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09